Your fact-checks will appear here
Available reporting shows no clinical trials of a product named “Memoblast” or “MemoBlast”; instead the search results center on Mesoblast — an established cellular-therapy company whose trials of mes...
Mesoblast’s remestemcel‑L (branded Ryoncil) has received U.S. FDA approval for pediatric steroid‑refractory acute graft‑versus‑host disease (SR‑aGvHD), according to multiple reports citing a December ...
Memoblast (remestemcel‑L, marketed as Ryoncil®/RYONCIL®/Ryoncil in Mesoblast materials) is an allogeneic bone‑marrow derived mesenchymal stromal cell therapy. The U.S. FDA granted approval for remeste...